Potential $463M Contract for Palantir; Potential Upside for Micron, Ford, Chemours and Penumbra
- June 05th, 2023
- 320 views
Palantir Technologies Inc. (NYSE: PLTR) has been awarded a significant five-year indefinite-delivery/indefinite-quantity contract with a maximum ceiling of $463,000,000. The contract aims to provide ongoing capabilities and support for select units of the U.S. Special Operations Command (USSOCOM) for a duration of one year.
Palantir's role will involve the development and sustainment efforts within the larger ecosystem of programs under the Program Executive Office (PEO) Special Operations Forces Digital Applications (SDA) portfolio.
The contracting activity is being carried out by USSOCOM, based in MacDill Air Force Base, Florida.
$PLTR closed at $15.24 on Monday, showing a positive movement of $0.72 (+4.96%)
Micron Technology, Inc. (Nasdaq: MU) received a price target raise from $70 to $82 at Wells Fargo.
Despite closing at $67.77 on Monday, this revised price target suggests a potential upside of $14.23 (+21.01%) for $MU, according to Wells Fargo's analysis.
Ford Motor Company (NYSE: F) was upgraded from Neutral to Buy at Citigroup, with the price target raised from $12.80 to $16.
With Monday's closing price at $12.59, this upgraded price target indicates a potential upside of $3.41 (+27.06%) for $F, based on Citigroup's analysis.
The Chemours Company (NYSE: CC) had its price target raised from $54 to $64 at BMO Capital.
Despite closing at $34.75 on Monday, this increased price target implies a potential upside of $29.25 (+84.20%) for $CC, according to BMO Capital's analysis.
Penumbra, Inc. (NYSE: PEN) witnessed a price target raise from $312 to $328 at BTIG.
With $PEN closing at $321.83 on Monday, this revised price target suggests a potential upside of $6.17 (+1.92%) based on BTIG's analysis.
These potential upsides are based on the assessments of the respective brokerage firms, investment firms, or analysts.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Tags
Post Your Comments
Want To Find Some News?
Recent Posts
-
December 05th, 2025
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025




Member Login